A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on determining the next steps for the osteoarthritis candidate.
Source: FierceBiotech
